MGI Tech Partners with Eva Holding Group to Transform Genomics in Brazil
São Paulo, October 22, 2025 – MGI Tech Co., Ltd. (MGI), a company focused on advancing life sciences, has announced a strategic partnership with Brazil’s Eva Holding Group. This collaboration aims to improve access to genomic technologies for Brazilian patients, particularly in the areas of human health, animal health, and agribusiness.
A key part of this agreement is the installation of advanced genetic sequencers, like the DNBSEQ-T7. This state-of-the-art system enhances the accuracy of cancer tracking and is already being utilized in Brazil’s largest genomic project. Notably, it is the first high-throughput sequencer with In Vitro Diagnostic (IVD) certification in Latin America, enabling its clinical application for the first time in Brazil.
“The DNBSEQ-T7 is exceptional for its ability to handle various tasks such as whole-genome and exome sequencing. It provides high-quality data at a lower cost,” said Carlos Carpio, MGI’s Senior Commercial Director for Latin America and General Manager in Brazil. This technology not only allows for a more thorough analysis of DNA but also enhances the quality of genomic data, improving the detection of genetic variants.
Eva Holding Group features several brands, each utilizing DNA to address different needs:
- Predictus Gene: Human predictive analysis through whole genome sequencing.
- OLLIN: Clinical diagnosis of rare diseases.
- Pet Nex: Genetic analysis for pets.
- Earth Biome: Genomics focused on livestock and agriculture.
Dr. Rene Pimenta da Silva Junior, CEO of OLLIN Análises Genômicas, and Dr. Carolina A. Barbosa, President of Eva Holding Group, expressed enthusiasm about the partnership. “MGI’s technology will significantly advance our innovative efforts, particularly benefiting patients in oncology and rare diseases through rapid genome analysis.”
As part of their strategic plan, Eva Holding Group will streamline its complex genomic operations in a dedicated technology park, enhancing efficiency and quality control.
The Importance of Genetic Sequencing
Genetic sequencing is vital in cancer screening, helping doctors identify genes linked to disease development. This allows for tailored treatment strategies, which can lead to better outcomes and higher survival rates. Furthermore, for hereditary cancers, this technology supports predictive medicine, enabling proactive health measures.
“Understanding the genetic risks of diseases allows for better preventive strategies and treatment choices tailored to each patient’s unique genetic background,” concluded Carlos Carpio.
About MGI
MGI is committed to revolutionizing life sciences through research, development, and production of genetic sequencing tools and technologies. Since its founding in 2016, MGI has become a leader in the field, providing high-quality genomic solutions across the globe.
About Eva Holding Group
Eva Holding Group is an innovative platform specializing in genomics and biotechnology, focusing on practical applications of DNA. With a national footprint and international partnerships, the group combines research and clinical services to pioneer advancements in precision medicine and applied genomics.
